Organization | Kessler Institute for Rehabilitation

Kessler Institute for Rehabilitation Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: West Orange NJ United States (1948)

Organization Overview

First Clinical Trial

2003

NCT00266864

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Kessler Institute for Rehabilitation | Kessler Medical Rehabilitation Research & Education Corporation

Active Ingredients

Drugs in Phase 4 Trials (5)

denosumab (prolia) (5 trials)

exenatide (byetta) (1 trial)

phenol (1 trial)

romosozumab (Evenity) (3 trials)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 3 Trials (1)

testosterone (delatestryl) (1 trial)

Drugs in Phase 2 Trials (2)

dalfampridine (ampyra) (1 trial)

oxybutynin (ditropan) (1 trial)

Drugs in Phase 1 Trials (3)

mometasone (elocon) (1 trial)

salmeterol (serevent) (1 trial)

tiotropium (spiriva) (1 trial)

Drugs in Other Trials (1)

modafinil (provigil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hypogonadism (Phase 3)

Insulin Resistance (Phase 4)

Osteoporosis (Phase 4)

Prediabetic State (Phase 4)

Spinal Cord Injuries (Phase 4)

Urinary Bladder, Neurogenic (Phase 2)

Wounds and Injuries (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 14
# of Trial APIs: 12